An exploration of storytelling and why it is important in Medical Affairs.
This resource is intended to provide Medical Affairs teams the rationale for meaningful ​value and impact measurements, as well as tips to support these:​
The objective of this White Paper is to guide Medical Affairs personnel on the key components of the legal, regulatory, and industry codes of practice requirements which are applicable to Medical Affairs in Pharma and Medical Devices industries, and how to identify and mitigate risks. This paper also includes company control frameworks for compliance with the requirements through policies, processes (usually captured in Standard Operating Procedures [SOPs]), systems, training, monitoring, and audit.
This S&G is intended to provide a common understanding of the framework in which External Education, led by Medical Affairs, ultimately benefits patients. The intent is to provide guidance and recommendations to Medical Affairs professionals and offer practical tools for planning, executing, and evaluating external education activities and funding determinations.
This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.
Altmetric’s top 10 most interesting publications of 2024
Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.
From the Spreadsheet Age to the Age of Generative AI: Where is your organization on the continuum of Insights Management? (And why no one “age” fits the needs of all teams.)